CLEAVE THERAPEUTICS
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.
CLEAVE THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care
Founded:
2010-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.cleavetherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(415) 562-8117
Email Addresses:
[email protected]
Total Funding:
89.95 M USD
Technology used in webpage:
SPF SSL By Default Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail Google Maps Microsoft Azure DNS GoDaddy DNS GStatic Google Static Content
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Investors List
Astellas Venture Management
Astellas Venture Management investment in Series C - Cleave Therapeutics
Celgene
Celgene investment in Series C - Cleave Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series C - Cleave Therapeutics
OrbiMed
OrbiMed investment in Series C - Cleave Therapeutics
5AM Ventures
5AM Ventures investment in Series C - Cleave Therapeutics
U.S. Venture Partners
U.S. Venture Partners investment in Series C - Cleave Therapeutics
Arcus Ventures
Arcus Ventures investment in Series C - Cleave Therapeutics
OrbiMed
OrbiMed investment in Series B - Cleave Therapeutics
Astellas Venture Management
Astellas Venture Management investment in Series B - Cleave Therapeutics
Clarus Ventures
Clarus Ventures investment in Series B - Cleave Therapeutics
Official Site Inspections
http://www.cleavetherapeutics.com
- Host name: 85.119.180.107.host.secureserver.net
- IP address: 107.180.119.85
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Cleave Therapeutics"
Cleave Therapeutics, Inc. - LinkedIn
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in ...See details»
Cleave Therapeutics - VentureRadar
" Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP), also known as p97, as a novel target in protein homeostasis and cellular stress …See details»
Cleave Therapeutics Company Profile 2024: Valuation, …
Cleave Therapeutics’s primary industry is Drug Discovery. Is Cleave Therapeutics a private or public company? Cleave Therapeutics is a Private company. What …See details»
Cleave Therapeutics, Inc.: Contact Details and Business Profile
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for …See details»
Cleave Therapeutics - Overview, News & Similar companies
Who is Cleave Therapeutics. Cleave Therapeutics is a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in protein homeostasis and cellular stress p athways for …See details»
Cleave Therapeutics - Org Chart, Teams, Culture
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative …See details»
Cleave Therapeutics - Funding, Financials, Valuation & Investors
Cleave Therapeutics is funded by 10 investors. Astellas Venture Management and Celgene are the most recent investors. Cleave Therapeutics has a post-money valuation in the range of …See details»
Organization | Cleave Biosciences, Inc.
Organization Overview. First Clinical Trial. 2014 NCT02223598. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Cleave Therapeutics, Inc. Active Ingredients. …See details»
Cleave Therapeutics CEO, Founder, Key Executive Team, Board of ...
She is the founder of the non-profit organization, The Clearity Foundation, which helps women with ovarian cancer improve their treatment options. In addition to Bright Peak Therapeutics, …See details»
Cleave Therapeutics Company Profile: Overview and Full News …
Cleave Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response …See details»
Cleave Therapeutics - Biocom CRO
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP), also known as p97, as a novel target in protein homeostasis and cellular stress …See details»
Cleave Therapeutics Announces Acquisition of Clinical and …
Jul 20, 2023 Cleave Therapeutics, Inc. Susan Kinkead [email protected] CASI Pharmaceuticals, Inc. Rui Zhang [email protected] Eikon Therapeutics, Inc. Lisa …See details»
Cleave Therapeutics - Contacts, Employees, Board Members
Cleave Therapeutics has 5 current employee profiles, including Consultant Kerry Kelly. Cleave Therapeutics has 9 board members and advisors, including Alfred Scheidegger . ContactsSee details»
Cleave Biosciences - Craft
Cleave Therapeutics is a developer of oncology pharmaceuticals designed to target neurodegeneration and pathways used by cancer cells to grow. It is engaged in the discovery …See details»
Cleave Therapeutics Appoints Amy Burroughs Chief Executive …
Aug 13, 2019 SAN FRANCISCO--(BUSINESS WIRE)--Cleave Therapeutics, Inc. (formerly Cleave Biosciences), a biopharmaceutical company focused on protein homeostasis and …See details»
Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor
Mar 8, 2021 Cleave Therapeutics is a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic …See details»
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful therapy was on track but faced an unclear future. Overseeing the …See details»
Research programme: cancer therapeutics - Cleave Therapeutics
Alternative Names: Inhibitors of p97 ATPase activity - Cleave Therapeutics; p97 inhibitors - Cleave Therapeutics Latest Information Update: 28 Sep 2022. Price : $50 * Buy Profile. Adis is …See details»
The Hippo Pathway in Breast Cancer: The Extracellular Matrix and …
3 days ago As one of the most prevalent malignant neoplasms among women globally, the optimization of therapeutic strategies for breast cancer has perpetually been a research …See details»
Cleavr Therapeutics - Crunchbase Company Profile & Funding
Cleavr Therapeutics is focused on the development of novel drug delivery targeting solutions to minimize healthy tissue damage.See details»